BCAB
Bioatla·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCAB
Bioatla, Inc.
A global clinical-stage biotech company focused on Conditionally Active Biologic antibody therapeutics for solid tumors
11085 Torreyana Road, San Diego, California 92121
--
Bioatla, Inc., is incorporated in Delaware. The company is a clinical-stage biopharmaceutical company dedicated to the development of a new class of highly specific and selective antibody-based therapies for the treatment of solid tumor cancers. The Company's Conditionally Active Biologics, or CAB, leverages its proprietary discoveries in tumor biology, enabling it to target known and widely validated tumor antigens that were previously difficult or impossible to target.
Company Financials
EPS
BCAB has released its 2025 Q3 earnings. EPS was reported at -0.27, versus the expected -0.3, beating expectations. The chart below visualizes how BCAB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
